Taysha Gene Therapies (NASDAQ:TSHA) vs. Rani Therapeutics (NASDAQ:RANI) Head-To-Head Survey

Rani Therapeutics (NASDAQ:RANI) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Valuation & Earnings

This table compares Rani Therapeutics and Taysha Gene Therapies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63 million	60.64	-$29.67 million	($0.41)	-1.95
Taysha Gene Therapies	$9.77 million	199.77	-$109.00 million	($0.38)	-15.76

Rani Therapeutics has higher earnings, but lower revenue than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Rani Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.

Insider and Institutional Ownership

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Rani Therapeutics and Taysha Gene Therapies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1	0	4	0	2.60
Taysha Gene Therapies	1	0	11	2	3.00

Rani Therapeutics presently has a consensus target price of $8.75, suggesting a potential upside of 996.63%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 113.18%. Given Rani Therapeutics’ higher probable upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Taysha Gene Therapies.

Profitability

This table compares Rani Therapeutics and Taysha Gene Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Taysha Gene Therapies	N/A	-66.22%	-46.75%

Summary

Taysha Gene Therapies beats Rani Therapeutics on 10 of the 14 factors compared between the two stocks.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.